Patents for A61P 35 - Antineoplastic agents (221,099)
06/2011
06/09/2011US20110136722 Drug Delivery Carrier
06/09/2011US20110136231 Methods and use of inducing apoptosis in cancer cells
06/09/2011US20110136221 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
06/09/2011US20110136185 Epothilones c, d, e, and f, preparation and compositions
06/09/2011US20110136173 Novel Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2 SCFV Fragment
06/09/2011US20110135770 Apples with high polyphenolic content
06/09/2011US20110135760 Use of Extracts or Materials Extracted From Piper Cubeba L. as an Effective Component in a Drug for the Treatment of Cancer Diseases
06/09/2011US20110135755 Combination therapies for treating neoplastic disease
06/09/2011US20110135745 Drink formula comprising fresh marine omega-3 oil and antioxidants
06/09/2011US20110135741 Sustained-release composition and method for producing the same
06/09/2011US20110135739 Oral Formulations of a Hedgehog Pathway Inhibitor
06/09/2011US20110135732 Multiple phase cross-linked compositions and uses thereof
06/09/2011US20110135729 Methods for Controlling Heat Generation of Magnetic Nanoparticles and Heat Generating Nanomaterials
06/09/2011US20110135715 Defensin-antigen fusion proteins
06/09/2011US20110135712 Biologically Active Taxane Analogs And Methods Of Treatment By Oral Administration
06/09/2011US20110135711 Methods and Compositions for Delivery of Catecholic Butanes for Treatment of Tumors
06/09/2011US20110135708 Dietary supplement - liquid filled gum
06/09/2011US20110135692 Anti-tumor immunotherapy
06/09/2011US20110135691 Immunomodulation by iap inhibitors
06/09/2011US20110135684 Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes in mature dendritic cells in vitro
06/09/2011US20110135683 Modified vaccinia virus ankara for the vaccnation of neonates
06/09/2011US20110135682 Recombinant Bicistronic Flaviviruses and Methods of Use Thereof
06/09/2011US20110135674 Markers of XMRV Infection and Uses Thereof
06/09/2011US20110135671 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
06/09/2011US20110135669 Synthetic agonists of tlr9
06/09/2011US20110135668 Compounds and compositions as protein kinase inhibitors
06/09/2011US20110135666 Regulatory b cells and their uses
06/09/2011US20110135663 Anti-igf-ir antibodies and uses thereof
06/09/2011US20110135658 Vhz for diagnosis and treatment of cancers
06/09/2011US20110135656 Method of treating cancer
06/09/2011US20110135654 Prostate cancer related gene styk1
06/09/2011US20110135653 Antibodies Against HER2 Truncated Variant CTF-611
06/09/2011US20110135652 Novel Use of Idbf
06/09/2011US20110135649 Vascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses Thereof
06/09/2011US20110135648 Anti-neublastin antibodies and uses thereof
06/09/2011US20110135647 Genes and polypeptides relating to breast cancers
06/09/2011US20110135643 Methods and compositions for prostate cancer immunotherapy
06/09/2011US20110135642 Pharmaceutical Compositions Comprising Antibodies Binding To EBV (Ebstein-Barr Virus) Protein BARF1
06/09/2011US20110135641 Radioprotectants targeting thrombospondin-1 and cd47
06/09/2011US20110135640 Identification of tumour-associated cell surface antigens for diagnosis and therapy
06/09/2011US20110135639 B lymphocyte stimulator assays
06/09/2011US20110135637 Trimodal cancer therapy
06/09/2011US20110135636 Recombinant Anti-Epidermal Growth Factor Receptor Antibody Compositions
06/09/2011US20110135635 Anti-alpha2 integrin antibodies and their uses
06/09/2011US20110135633 Chronic lymphocytic leukemia cell line
06/09/2011US20110135632 Methods for the modulation of angiogenesis
06/09/2011US20110135631 Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
06/09/2011US20110135630 Chemical modification of antibody fragments
06/09/2011US20110135629 EYA2S As Modifiers of the PTEN/AKT Pathway and Methods of Use
06/09/2011US20110135620 Prodrug activation in cancer cells using molecular switches
06/09/2011US20110135619 Polypeptides of Alicyclobacillus sp.
06/09/2011US20110135618 Methods of treating cancer with doxazolidine and prodrugs thereof
06/09/2011US20110135617 Pairing processes for preparing reactive cytotoxic T cells
06/09/2011US20110135603 Inhibitors of phosphatidylinositol 3-kinase
06/09/2011US20110135601 Bicycloaniline derivative
06/09/2011US20110135600 Bicyclic traizole derivatives for treating of tumors
06/09/2011US20110135598 Methods to diagnose and immunize against the virus causing human merkel cell carcinoma
06/09/2011US20110135595 Neuregulin based methods and compositions for treating cardiovascular disease
06/09/2011US20110135594 Oxindolyl inhibitor compounds
06/09/2011US20110135577 Superparamagnetic nanoparticles IN MEDICAL THERAPEUTICS and manufacturing method THEREOF
06/09/2011US20110135576 Dye conjugates of template-fixed peptidomimetics
06/09/2011US20110135571 Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
06/09/2011US20110135570 Anti-Tumor Cell Antigen Antibody Therapeutics
06/09/2011US20110135569 Method for therapeutic administration of radionucleosides
06/09/2011DE102009056886A1 cMet-Inhibitoren zur Behandlung der Endometriose cMet inhibitors for the treatment of endometriosis
06/09/2011DE102009056746A1 Transdermales therapeutisches System für die Verabreichung von Peptiden Transdermal therapeutic system for the administration of peptides
06/09/2011CA2782911A1 Liposome of irinotecan or its hydrochloride and preparation method thereof
06/09/2011CA2782684A1 Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
06/09/2011CA2782527A1 Uses of hypoxia-inducible factor inhibitors
06/09/2011CA2782484A1 Mybl2 peptides and vaccines containing the same
06/09/2011CA2782333A1 J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
06/09/2011CA2782330A1 Improved methods and compositions for detecting and treating cea-expressing cancers
06/09/2011CA2782299A1 Methods for treating cancers comprising k-ras mutations
06/09/2011CA2782271A1 Imp-3 oligopeptides and vaccines including the same
06/09/2011CA2782194A1 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
06/09/2011CA2781823A1 Spiroindolinone pyrrolidines
06/09/2011CA2781661A1 Ship1 modulators and methods related thereto
06/09/2011CA2778675A1 Combination therapy for treating cancer and diagnostic assays for use therein
06/09/2011CA2778586A1 Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
06/08/2011EP2330219A2 Method for drug discovery, disease treatment and diagnosis using metabolomics
06/08/2011EP2330213A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
06/08/2011EP2330197A2 Antagonistic selective binding agents of osteoprotegerin binding protein
06/08/2011EP2330131A1 Antibodies against HER2 truncated variant CTF-611
06/08/2011EP2330129A2 Anti-TNF antibodies, compositions, methods and uses
06/08/2011EP2330110A1 Platinum(II) complexes, preparation and use
06/08/2011EP2330105A1 Heteroaryl urea derivatives useful for inhibiting CHK1
06/08/2011EP2330100A1 An improved process for preparation of taxane derivatives
06/08/2011EP2329847A2 Use of an antibody or an immunotoxin that selectively binds to CD123 to impair hematologic cancer progenitor cells
06/08/2011EP2329842A2 Interleukin-1 inhibitors in the treatment of diseases
06/08/2011EP2329830A2 Antisense inhibition of PTP1B expression
06/08/2011EP2329828A1 Tetracyclines for the treatment of ischaemia
06/08/2011EP2329826A1 Tetracyclines for the treatment of multiple sclerosis
06/08/2011EP2329823A1 Method for improving absorbability of preparation, and preparation having improved absorbability
06/08/2011EP2329822A1 Compositions and methods of treatment of cancer
06/08/2011EP2329817A1 Retinoic acid receptor antagonists, miR-10a inhibitors and inhibitors of HOXB1 or HOXB3 repressors for treating pancreatic cancer
06/08/2011EP2329816A1 An anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof
06/08/2011EP2328932A1 Anti-cd5 antibodies
06/08/2011EP2328923A2 Cd133 epitopes
06/08/2011EP2328896A1 Tri-cyclic pyrazolopyridine kinase inhibitors
06/08/2011EP2328890A1 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors